Clinical Trials Logo

Filter by:
NCT ID: NCT05868915 Recruiting - Clinical trials for Advanced Solid Tumors

HV-101 for Patients With Advanced Solid Tumors

Start date: August 4, 2023
Phase: Phase 1
Study type: Interventional

Background: Tumor-infiltrating lymphocyte (TIL) therapy is a type of adoptive cellular therapy by harvesting infiltrated lymphocytes from tumors, culturing and amplifying them in vitro and then infusing back to treat patients. TIL therapy has shown strong efficacy for the treatment of solid tumors, and has achieved high objective response rates in multiple cancers. Objective: To evaluate the safety and efficacy of HV-101 for the treatment of advanced solid tumors. Eligibility: Adults aging 18-75 with advanced solid tumors Design: 1. Patients will undergo screening tests, including imaging procedures, heart and lung tests, and lab tests. 2. Freshly resected patient tumors were dissected by the surgeon. 3. TIL cells were isolated from the patient's tumor tissue in the laboratory, then cultured in vitro, activated and expanded. 4. HV-101 will be re-infused into the patient.

NCT ID: NCT05868876 Recruiting - Clinical trials for Advanced Malignant Tumors

A Phase Ia/Ib Open Label,Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK104 in Patients With Advanced Malignant Tumors

Start date: June 29, 2023
Phase: Phase 1
Study type: Interventional

A Phase Ia/Ib open label,clinical study evaluating the safety, tolerability and preliminary efficacy of AK127 in combination with AK104 in patients with advanced malignant tumors

NCT ID: NCT05868850 Completed - Chemotherapy Effect Clinical Trials

Application of Auricular Point Sticking in Patients With Taste Alteration

Start date: June 3, 2023
Phase: N/A
Study type: Interventional

To explore the intervention effect of auricular point sticking on chemotherapy-induced taste alterations in cancer patients, and analyze its relationship with quality of life, nutritional status and psychology of patients.

NCT ID: NCT05868707 Recruiting - Melanoma Clinical Trials

OH2 Injection in Melanoma

Start date: March 8, 2023
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy of OH2 injection in patients with unresectable or metastatic melanoma who have failed at least second-line standard therapy, using investigator-selected salvage chemotherapy or best supportive care (BSC) as controls.

NCT ID: NCT05868694 Recruiting - Apnea Clinical Trials

A Study of Breathing Sound-based Classification of Patients With Breathing Disorders

Start date: December 1, 2021
Phase:
Study type: Observational [Patient Registry]

Sleep-disordered breathing can damage the cardiovascular system, and may also lead to dysregulation of the autonomic nervous system, endocrine disorders, and hemodynamic changes, causing multi-system and multi-organ damage. Screening for potential central-type patients among patients with respiratory disorders can help provide scientific diagnosis and treatment decisions, thus achieving precise treatment. Currently, research on the identification of sleep-disordered breathing phenotypes is in its infancy. Sleep-disordered breathing phenotypes, such as obstructive and central respiratory events, vary widely among individuals. Compared to indirect methods such as RIP and SpO2, changes in breathing sounds and snoring during sleep can more directly reflect airway obstruction. Different types of sleep-disordered breathing exhibit different characteristics in terms of snoring. Patients with obstructive sleep apnea experience narrowing or blockage of the airway due to relaxation of the throat muscles during sleep, which leads to breathing pauses and hypopnea events, resulting in decreased blood oxygen levels, arousal, and snoring. Central sleep apnea is caused by problems with the brainstem or respiratory control center, leading to breathing pauses. Snoring is usually not very prominent in patients with central sleep apnea. This study aims to screen for potential central-type patients by analyzing upper airway sounds of patients with sleep-disordered breathing, in order to achieve precise treatment.

NCT ID: NCT05868564 Not yet recruiting - Clinical trials for Peripheral Arterial Disease

Atherectomy Followed With a Drug Coated Balloon in the Treatment of Long Femoropopliteal Lesions

Start date: July 1, 2023
Phase: N/A
Study type: Interventional

The study is a prospective, multicenter, randomized pilot study to evaluate the clinical outcome of the plaque atherectomy system followed by the UltrafreeTM drug coated balloon catheter versus the drug coated balloon in patients with chronic long femoropopliteal lesions.

NCT ID: NCT05868083 Recruiting - Clinical trials for Recurrent Glioblastoma Multiforme

The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the Recurrent Glioblastoma

Start date: June 24, 2022
Phase: Phase 1
Study type: Interventional

This is a single arm clinical study to estimate the safety, tolerability and pharmacokinetic (PK) characteristics of Chimeric Antigen Receptor-modified T cells (CAR-T) SNC-109 in patients with recurrent glioblastoma (r-GBM) and preliminarily evaluate the effectiveness, the immunogenicity of the product, as well as their correlation between the changes of cytokines from baseline level after cellular infusion.

NCT ID: NCT05868057 Completed - Clinical trials for Endometriosis, Uterine Fibroids, Male Hormone-sensitive Prostate Cancer, Assisted Reproduction

A Clinical Study Evaluating the Relative Bioavailability of SHR7280 Dry Suspension and Tablets

Start date: May 23, 2023
Phase: Phase 1
Study type: Interventional

To assess the relative bioavailability of SHR7280 dry suspension and tablets in healthy subjects. To assess the safety and tolerability of a single dose of SHR7280 dry suspension and tablets.

NCT ID: NCT05867992 Not yet recruiting - Clinical trials for Traumatic Brain Injury

Multiomic Analysis of Serum in Acute Period of Traumatic Brain Injury

MASTER-TBI
Start date: April 1, 2024
Phase:
Study type: Observational

The goal of this experimental observation study is to figure out differently expressed biomarkers in serum in traumatic brain injury patients, compared with bone fracture patients. The main questions it aims to answer are: 1. Which proteins and metabolites are differently expressed in TBI patients' serum? 2. Which proteins or metabolites can serve as the new serum biomarkers for diagnosing TBI? Participants will be treated by routine treatments, and their serum samples will be collected in the emergency room.

NCT ID: NCT05867901 Recruiting - Clinical trials for Gastrointestinal Stromal Tumors

Clinical Research of Drug Holiday Based on MRD Detection in GIST Patients at High Risk of Recurrence

Start date: June 1, 2023
Phase:
Study type: Observational

This study is aimed: - to evaluate the dynamic monitoring value of MRD detection for postoperative recurrence in high-risk GIST patients; - to evaluate the effect of drug holiday mode based on MRD detection on progression-free Survival (PFS) and/or overall survival (OS) after drug withdrawal for high-risk GIST patients who have achieved disease control after long-term use of imatinib; ③ to investigate the response rate of imatinib re-use in patients who developed disease progression after drug withdrawal; ④ to explore whether the "drug holiday" treatment mode based on MRD detection could delay the occurrence of secondary imatinib resistance mutations for high-risk GIST patients with long-term use of imatinib after surgery.